Hyaluronic Acid and Adelmidrol (Hyadrol®) in Patients With Degenerative Joint Disease

Launched by UNIVERSITY OF ROMA LA SAPIENZA · Jul 11, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new treatment for patients with degenerative joint diseases, specifically arthritis in the hip and certain hand joints. The treatment combines two substances: hyaluronic acid, which helps lubricate the joints, and Adelmidrol, which may reduce inflammation. The goal is to see if this combination can safely relieve pain and improve joint function for people suffering from arthritis.

To participate in the trial, you need to be at least 40 years old and have a specific type of arthritis that causes moderate to severe pain. You should not have taken certain anti-inflammatory medications or undergone specific treatments in the months leading up to the trial. If you decide to join, you will receive the study treatment and be monitored by healthcare professionals. Your participation will help researchers understand if this new approach can be an effective option for managing arthritis pain.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • age ≥ 40 years;
• • both genders;
• • diagnosis of stage II-III coxarthrosis or rhizoarthrosis according to radiological classification (Kellgren and Lawrence or modified Eaton-Littler criteria respectively)
• • pain intensity ≥ 5 on NRS;
• • wash-out for at least two weeks from anti-inflammatory drugs before enrollment;
• • compliant patients;
• • signed informed consent.
• Exclusion Criteria:
• • age \< 40 years;
• • presence of concomitant inflammatory systemic pathologies (e.g.: rheumatoid arthritis, etc.);
• • severe and progressive clinical conditions,
• • NSAIDs therapy in the 2 weeks prior to enrollment;
• • corticosteroid therapy in the 3 months prior to enrollment;
• • chondroprotectors intake in the 6 months prior to enrollment;
• • arthroscopic procedures or intra-articular visco-supplementation in the 6 months prior to enrollment;
• • presence of cognitive impairment;
• • ongoing rehabilitation and/or physiotherapy;
• • allergy or hypersensitivity to the study treatment;
• • pregnant and/or lactating female subjects;
• • not compliant patients;
• • denied informed consent.